How can PRM technology help analyze low-abundance proteins?
In proteomics research and clinical applications, quantitative detection of low-abundance proteins has always been a technical bottleneck. Despite their extremely low expression levels, these proteins often have significant biological importance, such as inflammatory factors, cytokines, transcription factors, or early disease markers. The DDA (Data Dependent Acquisition) mode is limited by acquisition depth and dynamic range, making it difficult to consistently detect these low-abundance targets. PRM (Parallel Reaction Monitoring) technology, with its high selectivity and sensitivity, provides an effective solution for quantitative analysis of low-abundance proteins. This article will delve into the core advantages, mechanisms, and technical platform capabilities of PRM technology in detecting low-abundance proteins.
1. Challenges in Analyzing Low-Abundance Proteins
1. Wide Dynamic Range: Protein concentrations in plasma can span 12 orders of magnitude, making the signals of low-abundance proteins easily masked by high-abundance components.
2. Low Signal-to-Noise Ratio: The signals of target proteins are weak and can easily be overwhelmed by interfering ions in a complex matrix background.
3. Poor Reproducibility: Other proteomics methods have poor quantitative stability near detection limits, leading to significant cross-sample comparison errors.
4. Lack of Stable Internal Standards: Low-abundance targets lack reliable reference points and are easily affected by instrument fluctuations or pre-treatment differences.
2. How Does PRM Technology Address These Challenges?
PRM is a targeted mass spectrometry technology operating on high-resolution platforms such as Orbitrap, characterized by selective fragmentation of specific precursor ions followed by full scan acquisition of all fragment ions, thereby enhancing the detection capability of low-abundance proteins across multiple dimensions.
Key advantages include:
1. High Resolution Eliminates Background Interference
(1) The Orbitrap mass spectrometer commonly used in PRM technology can provide a resolution greater than 30,000, effectively distinguishing interfering ions with similar mass-to-charge ratios.
(2) Accurate mass selection windows (±5 ppm) significantly improve the signal-to-noise ratio and enhance the recognition capability of low-abundance signals.
2. Enhanced Quantitative Specificity with Multiple Fragment Ions
(1) Unlike SRM which can only acquire 1-2 transitions, PRM can simultaneously record all fragment ions, allowing for the selection of the optimal combination for quantification.
(2) The multi-dimensional confirmation mechanism significantly enhances the credibility of low-abundance signals.
3. Free Choice of Quantitative Ions Improves Reproducibility
Researchers can freely choose the best ion pairs for quantification based on each run's data, alleviating signal instability issues.
4. Accurate Calibration with Stable Isotope Internal Standards
Synthetic SIL peptides exhibit identical mass spectrometric behavior to target peptides, effectively compensating for injection fluctuations and ionization efficiency differences.
3. Key Factors Affecting PRM Technology's Effectiveness in Detecting Low-Abundance Proteins
1. Quality of Peptide Selection
(1) Preferential selection of characteristic peptides with good ion response, no modifications, and no ambiguity.
(2) Can be assisted by DIA data and database prediction tools (e.g., PeptideAtlas, Prosit) for screening.
2. Sample Pre-treatment and Enrichment Techniques
Using methods such as protein desalting, SPE solid-phase extraction, and immunoenrichment (e.g., SISCAPA) to remove high-abundance backgrounds and enhance the proportion of target signals.
3. Optimization of Chromatographic Separation Performance
(1) Improving retention time stability to prevent target signals from being obscured during complex elution processes.
(2) Use of multi-dimensional chromatography or extended gradients to enhance separation.
4. Adjustment of Mass Spectrometry Acquisition Parameters
Adjusting isolation window size, injection time (IT), and automatic gain control (AGC) settings to ensure comprehensive collection of low-abundance ions.
4. PRM Technology Platform of Biotech Park
Biotech Park has accumulated rich technical experience in targeted quantitative analysis of low-abundance proteins and has established the following advantageous systems:
1. Advanced Equipment Platform: Utilizing high-resolution instruments such as Orbitrap Exploris 480, providing high-sensitivity and high-throughput PRM analytic capabilities.
2. Custom Method Development: Personalized design of peptides, optimization of parameters, and customization of SIL internal standards based on client target characteristics.
3. Comprehensive Standardized Quality Control: Strict quality control checkpoints are set from sample processing, peptide synthesis, data analysis to project reporting.
4. Compatibility with Complex Samples: Providing enrichment and pre-treatment solutions for high-background samples such as plasma, cerebrospinal fluid, and cell lysates.
PRM technology, with its high selectivity, high sensitivity, and consistent quantitation, is gradually becoming the mainstream method for analyzing low-abundance proteins. Faced with disease marker validation, drug target research, and other scenarios, PRM provides strong data support for researchers. Biotech Park will continue to optimize PRM platform capabilities to provide clients with more accurate and reliable low-abundance protein quantitation services.
Biotech Park—A Quality Service Provider in Biological Product Characterization and Multi-omics Mass Spectrometry Detection
Related Services:
How to order?
